ENGLEWOOD, Colo., June 2, 2015 /PRNewswire/ -- Rosewind Corporation (RSWN) announced that, after necessary state filings, the company will be known as Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions. The corporate name change was approved by shareholders at a special meeting of Rosewind Corp. shareholders held on June 1, 2015.
Josh Disbrow, Chief Executive Officer of the Company, commented, "We are excited to announce the upcoming official corporate name change and the rebranding of our company within the specialty pharmaceuticals industry. With our current management team, we believe we are well positioned to replicate with Aytu our previous success with pharmaceutical companies, relying on our proven track record for building successful commercial-stage specialty healthcare companies. The name Aytu is meant to reflect this concept by combining the strengths and experience gained at our two previous 'A' companies: Arbor Pharmaceuticals, which we founded, built into a revenue-generating enterprise, and successfully sold; and Ampio Pharmaceuticals, from which our two current assets were originally developed. We look forward to building immediate value for Aytu by accelerating our internal asset development and seeking to acquire complementary urological products."
In addition to the name change, Rosewind shareholders approved the Company's reincorporation in the State of Delaware from the current State of Colorado, as well as a 12.174 to 1 reverse split of the Company's common stock and adoption of an employee stock option plan. The details of these items can be found in a Form 8-K filed today with the SEC. Additionally, and subject to FINRA approval, the company ticker is expected to change from RSWN to AYTU, and will continue to trade on the OTCQB Marketplace. The reverse stock split, name change and ticker change are expected to occur as soon as June 8